Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9667 | 0.94 | CYP3A4 (0.50) | POLBCYP3A4TSHRPIK3CAALDH1A1 | |
| Hydrochloric Acid SCHEMBL154618 | 0.92 | POLB (0.48) | POLBCYP3A4TSHRPIK3CAALDH1A1 | |
| Hydrochloric Acid SCHEMBL6369794 | 0.92 | POLB (0.48) | POLBCYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL8504753 | 0.92 | POLB (0.48) | POLBCYP3A4TSHRPIK3CAALDH1A1 | |
| Hydrochloric Acid SCHEMBL526310 | 0.92 | POLB (0.48) | POLBCYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL3220414 | 0.92 | POLB (0.48) | POLBCYP3A4TSHRPIK3CAALDH1A1 | |
| Sulfuric Acid SCHEMBL8521096 | 0.85 | ALDH1A1 (0.41) | POLBCYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL29384787 | 0.82 | CYP3A4 (0.62) | POLBCYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL33944 | 0.82 | CYP3A4 (0.62) | POLBCYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL31607635 | 0.80 | ALDH1A1 (0.59) | POLBCYP3A4TSHRPIK3CAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117897058-A | Collagen compositions and methods of use thereof | 现代牧场股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240099955-A1 | SKINCARE COMPOSITIONS AND METHODS OF USE THEREOF | HTL BIOTECHNOLOGY INNOVATION INC. | 2024-03-28 | — | — | US | disclosed |
| US-20240034985-A1 | COMPOSITIONS FROM A BACTERIAL ORGANISM AND USES THEREOF | LIBERTY BIOSECURITY, LLC | 2024-02-01 | — | — | US | disclosed |
| CN-117417434-A | Recombinant human XXI type collagen and preparation method and application thereof | 泰炣生物科技(深圳)有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20230364000-A1 | COMPOSITIONS COMPRISING COMBINATIONS OF COLLAGEN OR ELASTIN POLYPEPTIDES WITH ACTIVE INGREDIENTS AND METHODS OF USING SAME | GELTOR, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-117042752-A | Compositions from bacterial organisms and uses thereof | 自由生物安全公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116847871-A | Skin care compositions and methods of use | 现代牧场股份有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116669696-A | Compositions comprising a combination of a collagen or elastin polypeptide and an active ingredient and methods of use thereof | 格尔托公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116178525-A | Recombinant collagen and elastin molecules and uses thereof | 格尔托公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20220127333-A1 | RECOMBINANT ELASTIN AND PRODUCTION THEREOF | GELTOR, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20050124691-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | KELLEHER JUDITH A (US) | 2005-06-09 | — | — | US | disclosed |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6441032-B1 | TREATING SYSTEMIC LUPIS AND MULTIPLE SCLEROSIS | CENTAUR PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6433008-B1 | TREATING PARKINSON*S, ALZHEIMER*S, AUTOIMMUNE AND RHEUMATIC DISEASES; HUMAN IMMUNODEFICIENCY VIRUS (HIV) DEMENTIA, AND INFLAMMATION | CENTAUR PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1025079-A1 | $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-08-09 | — | — | EP | disclosed |
| EP-1005463-A1 | FURANSULFONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| US-6046232-A | THERAPEUTICS FOR TREATING AND/OR PREVENTING NEUROLOGICAL, AUTOIMMUNE AND INFLAMMATORY CONDITIONS IN MAMMALS AND AS ANALYTICAL REAGENTS FOR DETECTING FREE RADICALS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5994396-A | Furansulfonic acid derivatives and pharmaceutical compositions containing the same | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1999020601-A1 | α-ARYL-N-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999009022-A1 | FURANSULFONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124691-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | NLN, NAT1, SNCA | POLB 985/4885CYP3A4 727/4885TSHR 2456/4885 |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | NLN, NAT1, SNCA | POLB 1015/4885CYP3A4 760/4885TSHR 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.